The MIH1 monoclonal antibody specifically binds to CD274, which is also known as, B7 homolog 1 (B7-H1), Programmed cell death 1 ligand 1 (PDCD1 ligand, PDCD1L1, PDCD1LG1), or Programmed death ligand 1 (PD-L1, PDL1). CD274 and PD-L2 (CD273) are type I transmembrane glycoproteins that belong to the B7 family and serve as ligands for CD279 (Program Death 1/PD-1). CD274 is expressed on antigen-presenting cells including activated monocytes/macrophages and dendritic cells, as well as, activated T cells, and keratinocytes. CD274 is also expressed on placental trophoblasts, myocardial endothelium, cortical thymic epithelial cells, and on most carcinomas. CD274 plays an important role in regulating T cell responses. The MIH1 antibody blocks CD279 binding to CD274 and can enhance the proliferation and cytokine production of activated T cells.
The antibody was conjugated to an oligonucleotide that contains an antibody clone-specific barcode (ABC) flanked by a poly-A tail on the 3' end and a PCR handle (PCR primer binding site) on the 5' end. The ABC for this antibody was designed to be used with other BD AbSeq oligonucleotides conjugated to other antibodies. All AbSeq ABC sequences were selected in silico to be unique from human and mouse genomes, have low predicted secondary structure, and have high Hamming distance within the BD AbSeq portfolio, to allow for sequencing error correction and unique mapping. The poly-A tail of the oligonucleotide allows the ABC to be captured by the BD Rhapsody™ system or other oligo-dT-based capture systems. The 5' PCR handle allows for efficient sequencing library generation for Illumina sequencing platforms.